Publications - Claudia F. Lucchinetti, M.D.

Back to research profile

  1. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 Apr 25. [Epub ahead of print]
    View PubMed
  2. Iorio R, Lucchinetti CF, Lennon VA, Farrugia G, Pasricha PJ, Weinshenker BG, Pittock SJ. Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):240-5. Epub 2012 Dec 01.
    View PubMed
  3. Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler. 2013 Feb; 19(2):188-98. Epub 2012 Jun 26.
    View PubMed
  4. Bruck W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, Metz I. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol. 2012 Sep; 72(3):385-94.
    View PubMed
  5. Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, Costanzi C, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Shuster EA, Pittock SJ. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012 Aug; 69(8):1039-43.
    View PubMed
  6. Abou Zeid N, Pirko I, Erickson B, Weigand SD, Thomsen KM, Scheithauer B, Parisi JE, Giannini C, Linbo L, Lucchinetti CF. Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions. Neurology. 2012 May 22; 78(21):1655-62. Epub 2012 May 09.
    View PubMed
  7. Filippi M, Rocca MA, Barkhof F, Bruck W, Chen JT, Comi G, DeLuca G, De Stefano N, Erickson BJ, Evangelou N, Fazekas F, Geurts JJ, Lucchinetti C, Miller DH, Pelletier D, Popescu BF, Lassmann H, Attendees of the Correlation between Pathological MRI findings Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012 Apr; 11(4):349-60. Epub 2012 Mar 19.
    View PubMed
  8. Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, Fallier-Becker P, Noell S, Lennon VA. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012 Jan 24; 109(4):1245-50. Epub 2011 Nov 29.
    View PubMed
  9. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012; 7:185-217.
    View PubMed
  10. Costanzi C, Bourdette D, Parisi JE, Woltjer R, Rodriguez F, Steensma D, Lucchinetti CF. Crystal-storing histiocytosis: An unusual relapsing inflammatory CNS disorder. Multiple Sclerosis and Related Disorders. 2012; 1(2):95-9.
  11. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012; 12:11. Epub 2012 Mar 07.
    View PubMed
  12. Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J, Harris C, Herbert J, Li D, Lincoln JA, Lisak R, Lublin FD, Lucchinetti CF, Moore W, Naismith RT, Oehninger C, Simo J, Sormani MP. Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course. International Journal of MS Care. 2012; 14(3):105-14.
  13. Lennon VA, Hinson SR, Romero MF, Fallier-Becker P, Lucchinetti CF. Reply to Rossi et al.: Immunohistopathological findings in neuromyelitis optica concur with immunobiological observations in vitro. Proc Natl Acad Sci U S A. 2012; 109(24):E1512.
  14. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Bruck W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011 Dec 8; 365(23):2188-97.
    View PubMed
  15. Iorio R, Lucchinetti CF, Lennon VA, Costanzi C, Hinson S, Weinshenker BG, Pittock SJ. Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology. 2011 Oct 25; 77(17):1644-6. Epub 2011 Oct 12.
    View PubMed
  16. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011 Aug 16; 77(7):659-66. Epub 2011 Aug 3.
    View PubMed
  17. Smith JH, Dhamija R, Moseley BD, Sandroni P, Lucchinetti CF, Lennon VA, Kantarci OH. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. Arch Neurol. 2011 Aug; 68(8):1069-72.
    View PubMed
  18. Roemer SF, Scheithauer BW, Varnavas GG, Lucchinetti CF. Tumefactive demyelination and glioblastoma: a rare collision lesion. Clin Neuropathol. 2011 Jul-Aug; 30(4):186-91.
    View PubMed
  19. Magana SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, Rodriguez M, Thomsen K, Weigand S, Mandrekar J, Linbo L, Lucchinetti CF. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011 Jul; 68(7):870-8. Epub 2011 Mar 14.
    View PubMed
  20. Popescu BF, Bunyan RF, Parisi JE, Ransohoff RM, Lucchinetti CF. A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology. 2011 May 17; 76(20):1705-10.
    View PubMed
  21. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gomez JA, Newell K, Mandler RN, Pittock SJ, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011 Apr 5; 76(14):1229-37. Epub 2011 Mar 02.
    View PubMed
  22. Bunyan RF, Popescu BF, Carter JL, Caselli RJ, Parisi JE, Lucchinetti CF. Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination. Arch Neurol. 2011 Apr; 68(4):525-8.
    View PubMed
  23. Almekhlafi MA, Clark AW, Lucchinetti CF, Zhang Y, Power C, Bell RB. Neuromyelitis optica with extensive active brain involvement: an autopsy study. Arch Neurol. 2011 Apr; 68(4):508-12.
    View PubMed
  24. Jones DT, Mateen FJ, Lucchinetti CF, Jack CR Jr, Welker KM. Default mode network disruption secondary to a lesion in the anterior thalamus. Arch Neurol. 2011 Feb; 68(2):242-7. Epub 2010 Oct 11.
    View PubMed
  25. Popescu BF, Parisi JE, Cabrera-Gomez JA, Newell K, Mandler RN, Pittock SJ, Lennon VA, Weinshenker BG, Lucchinetti CF. Absence of cortical demyelination in neuromyelitis optica. Neurology. 2010 Dec 7; 75(23):2103-9.
    View PubMed
  26. Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, Lennon VA, McKeon A, Carpenter AF, Miller GM, Pittock SJ. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010 Nov; 68(5):757-61.
    View PubMed
  27. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010 Oct; 133(10):2983-98. Epub 2010 Sep 20.
    View PubMed
  28. Pittock SJ, Parisi JE, McKeon A, Roemer SF, Lucchinetti CF, Tan KM, Keegan BM, Hunter SF, Duncan PR, Baehring JM, Matsumoto JY, Lennon VA. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol. 2010 Sep; 67(9):1109-15.
    View PubMed
  29. Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, Roemer SF, Thomsen KM, Mandrekar JN, Erickson BJ, Lucchinetti CF. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 2010 Feb; 133(Pt 2):333-48. Epub 2010 Feb 03.
    View PubMed
  30. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol. 2009 Nov; 31(4):439-53. Epub 2009 Sep 25.
    View PubMed
  31. Kale N, Pittock SJ, Lennon VA, Thomsen K, Roemer SF, McKeon A, Lucchinetti CF. Humoral MS Pathology (Pattern II) is not Associated with NMO-IgG Arch Neurol. 2009 Oct; 66(10):1298-9.
  32. Staff NP, Lucchinetti CF, Keegan BM. Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol. 2009 Sep; 66(9):1139-43.
    View PubMed
  33. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, Lucchinetti CF, Weinshenker BG, Wingerchuk DM, Shuster EA, Pittock SJ. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009 Sep; 66(9):1134-8.
    View PubMed
  34. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009 Sep; 66(9):1128-33.
    View PubMed
  35. Magana SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol. 2009 Aug; 66(8):964-6.
    View PubMed
  36. Daniels TB, Pollock BE, Miller RC, Lucchinetti CF, Leavitt JA, Brown PD. Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: case report. J Neurooncol. 2009 Jun; 93(2):263-7. Epub 2008 Dec 20.
    View PubMed
  37. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009 May; 132(Pt 5):1175-89. Epub 2009 Mar 31.
    View PubMed
  38. Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, Shuster E, Kantarci OH, Lucchinetti CF, Weinshenker BG. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009 Feb 24; 72(8):712-7.
    View PubMed
  39. McKeon A, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, Chan KH, Weinshenker BG, Apiwattinakul M, Wingerchuk DM, Pittock SJ. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009 Jan; 39(1):87-90.
    View PubMed
  40. Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, Lucas M, Basso AS, Khoury SJ, Lucchinetti CF, Cohen IR, Weiner HL. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A. 2008 Dec 2; 105(48):18889-94. Epub 2008 Nov 21.
    View PubMed
  41. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, Howe CL, Pittock SJ, Lennon VA. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008 Oct 27; 205(11):2473-81. Epub 2008 Oct 06.
    View PubMed
  42. Rodriguez FJ, Gamez JD, Vrana JA, Theis JD, Giannini C, Scheithauer BW, Parisi JE, Lucchinetti CF, Pendlebury WW, Bergen HR 3rd, Dogan A. Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest. 2008 Oct; 88(10):1024-37. Epub 2008 Aug 18.
    View PubMed
  43. McKeon A, Lennon VA, Lotze T, Tenenbaum S, Ness JM, Rensel M, Kuntz NL, Fryer JP, Homburger H, Hunter J, Weinshenker BG, Krecke K, Lucchinetti CF, Pittock SJ. CNS aquaporin-4 autoimmunity in children. Neurology. 2008 Jul 8; 71(2):93-100. Epub 2008 May 28.
    View PubMed
  44. Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson BJ, Konig F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Bruck W. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008 Jul; 131(Pt 7):1759-75. Epub 2008 Jun 05.
    View PubMed
  45. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008 Jun 3; 70(23):2197-200. Epub 2008 Apr 23.
    View PubMed
  46. Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, Diamandis EP. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem. 2008 Jun; 389(6):739-45.
    View PubMed
  47. Porter AB, Giannini C, Kaufmann T, Lucchinetti CF, Wu W, Decker PA, Atkinson JL, O'Neill BP. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol. 2008 May; 63(5):662-7.
    View PubMed
  48. Keegan BM, Giannini C, Parisi JE, Lucchinetti CF, Boeve BF, Josephs KA. Sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MS. Neurology. 2008 Mar 25; 70(13 Pt 2):1128-33. Epub 2008 Feb 20.
    View PubMed
  49. Young NP, Weinshenker BG, Lucchinetti CF. Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol. 2008 Feb; 28(1):84-94.
    View PubMed
  50. Lucchinetti CF. Multiple sclerosis and the spectrum of CNS inflammatory demyelinating diseases. Semin Neurol. 2008 Feb; 28(1):3-6.
    View PubMed
  51. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008 Jan 29; 70(5):344-52. Epub 2007 Dec 19.
    View PubMed
  52. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zephir H, Moder K, Weinshenker BG. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008 Jan; 65(1):78-83.
    View PubMed
  53. Lucchinetti C. Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders. Curr Top Microbiol Immunol. 2008; 318:19-43.
    View PubMed
  54. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007 Dec 11; 69(24):2221-31. Epub 2007 Oct 10.
    View PubMed
  55. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock S, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurology. 2007 Sep; 6(9):805-15.
  56. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol. 2007 Jul; 187(1-2):126-38. Epub 2007 May 21.
    View PubMed
  57. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol. 2007 Jun; 20(3):343-50.
    View PubMed
  58. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, Atkins HL, Azzarelli B, Kolar OJ, Bruck W. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007 May; 130(Pt 5):1254-62.
    View PubMed
  59. Vana AC, Lucchinetti CF, Le TQ, Armstrong RC. Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS. Glia. 2007 May; 55(7):687-97.
    View PubMed
  60. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007 May; 130(Pt 5):1194-205.
    View PubMed
  61. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007 Apr; 17(2):210-8.
    View PubMed
  62. Pittock SJ, Lucchinetti CF. The pathology of MS: new insights and potential clinical applications. Neurologist. 2007 Mar; 13(2):45-56.
    View PubMed
  63. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007 Feb 27; 68(9):634-42.
    View PubMed
  64. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007 Feb 20; 68(8):603-5.
    View PubMed
  65. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Bruck W, Rauschka H, Schmidbauer M, Lassmann H. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007 Jan; 17(1):38-44.
    View PubMed
  66. Pittock SJ, Reindl M, Achenbach S, Berger T, Bruck W, Konig F, Morales Y, Lassmann H, Bryant S, Moore SB, Keegan BM, Lucchinetti CF. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler. 2007 Jan; 13(1):7-16.
    View PubMed
  67. Hu WT, Kantarci OH, Merritt JL 2nd, McGrann P, Dyck PJ, Lucchinetti CF, Tippmann-Peikert M. Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery. Arch Neurol. 2007 Jan; 64(1):126-8.
    View PubMed
  68. Lucchinetti C. Advances in Neuropathology of MS.Pathogenic and Therapeutic Implications. Continuum. 2007; 13(5):86-116.
  69. Lucchinetti CF. Advances in the neuropathology of multiple sclerosis: Evolving pathogenic insights. CONTINUUM Lifelong Learn. Neurol. 2007; 13(5 MULTIPL.SCLEROSIS):86-116.
  70. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Bruck W, Lucchinetti C, Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006 Dec; 129(Pt 12):3165-72. Epub 2006 Aug 18.
    View PubMed
  71. Miller RC, Lachance DH, Lucchinetti CF, Keegan BM, Gavrilova RH, Brown PD, Weinshenker BG, Rodriguez M. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1178-86. Epub 2006 Sep 11.
    View PubMed
  72. Pittock SJ, Lucchinetti CF. Inflammatory transverse myelitis: evolving concepts. Curr Opin Neurol. 2006 Aug; 19(4):362-8.
    View PubMed
  73. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006 Jul; 63(7):964-8.
    View PubMed
  74. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23; 66(10):1485-9.
    View PubMed
  75. Schwartz KM, Erickson BJ, Lucchinetti C. Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology. Neuroradiology. 2006 Mar; 48(3):143-9. Epub 2006 Jan 31.
    View PubMed
  76. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006 Mar; 59(3):566-9.
    View PubMed
  77. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006 Mar; 63(3):390-6.
    View PubMed
  78. Castillo P, Woodruff B, Caselli R, Vernino S, Lucchinetti C, Swanson J, Noseworthy J, Aksamit A, Carter J, Sirven J, Hunder G, Fatourechi V, Mokri B, Drubach D, Pittock S, Lennon V, Boeve B. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006 Feb; 63(2):197-202.
  79. Morales Y, Parisi JE, Lucchinetti CF. The pathology of multiple sclerosis: evidence for heterogeneity. Adv Neurol. 2006; 98:27-45.
    View PubMed
  80. Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA. NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers. 2006; 22(4):197-206.
    View PubMed
  81. Fox RJ, Kivisakk P, Lee JC, Tucky B, Lucchinetti C, Rudick RA, Ransohoff RM. Chemokine receptors as biomarkers in multiple sclerosis. Dis Markers. 2006; 22(4):227-33.
    View PubMed
  82. Pittock SJ, McClelland RL, Achenbach SJ, Konig F, Bitsch A, Bruck W, Lassmann H, Parisi JE, Scheithauer BW, Rodriguez M, Weinshenker BG, Lucchinetti CF. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1693-7.
    View PubMed
  83. Kantarci OH, Morales Y, Ziemer PA, Hebrink DD, Mahad DJ, Atkinson EJ, Achenbach SJ, De Andrade M, Mack M, Ransohoff RM, Lassmann H, Bruck W, Weinshenker BG, Lucchinetti CF. CCR5 Delta 32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol. 2005 Dec; 169(1-2):137-43 Epub 2005 Sep 22.
    View PubMed
  84. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 Nov; 128(Part 11):2705-12.
    View PubMed
  85. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BAC, Hauser S, Racke MK. Characterizing the mechanisms of progression in multiple sclerosis - Evidence and new hypotheses for future directions. Arch Neurol. 2005 Sep; 62(9):1345-56.
    View PubMed
  86. Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005 Aug 13-19; 366(9485):579-82.
    View PubMed
  87. Cox A, Coles A, Antoun N, Malik O, Lucchinetti C, Compston A. Recurrent myelitis and optic neuritis in a 29-year-old woman. Lancet Neurol. 2005 Aug; 4(8):510-6.
    View PubMed
  88. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, Kim KK, Killmann MW, Lennon VA. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005 Jul; 58(1):96-107.
    View PubMed
  89. Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, Leel-Ossy L, Ordinario AT, Bruck W, Lassmann H. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain. 2005 May; 128(Part 5):979-87.
    View PubMed
  90. Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005 Apr 12; 64(7):1267-9.
    View PubMed
  91. Lucchinetti CF. Update on the international project on pathologic correlates in MS. Mult Scler. 2005 Feb; 11(1):99-100.
    View PubMed
  92. Lucchinetti CF, Parisi J, Bruck W. The pathology of multiple sclerosis. Neurol Clin. 2005 Feb; 23(1):77-105.
    View PubMed
  93. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17; 364(9451):2106-12.
    View PubMed
  94. Lucchinetti C, Bruck W. The pathology of primary progressive multiple sclerosis. Mult Scler. 2004 Jun; 10(Suppl 1):S23-S30.
    View PubMed
  95. Mahad DJ, Trebst C, Kivisakk P, Staugaitis SM, Tucky B, Wei T, Lucchinetti CF, Lassmann H, Ransohoff RM. Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J Neuropathol Exp Neurol. 2004 Mar; 63(3):262-73.
    View PubMed
  96. Hoftberger R, Aboul-Enein F, Brueck W, Lucchinetti C, Rodriguez M, Schmidbauer M, Jellinger K, Lassmann H. Expression of major histocompatibility complex Class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004 Jan; 14(1):43-50.
    View PubMed
  97. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Ann Neurol 2003 May; 53(5):580-7.
    View PubMed
  98. Trebst C, Staugaitis SM, Kivisakk P, Mahad D, Cathcart MK, Tucky B, Wei T, Rani MRS, Horuk R, Aldape KD, Pardo CA, Lucchinetti CF, Lassmann H, Ransohoff RM. CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol. 2003 Feb; 162(2):427-38.
    View PubMed
  99. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, Lucchinetti C, Schmidbauer M, Jellinger K, Lassmann H. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. Journal of Neuropathology & Experimental Neurology. 2003 Jan; 62(1):25-33.
    View PubMed
  100. O'Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschauer F, Kinkel RP, Bolibrush D, Cohen J, Freedman M, Webb U, Rabinowicz H, Metz LM, Patry D, Yeung M, Peters S, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, St MRI predictors of early conversion to clinically definite MS in the CHAMPS Placebo Group. Neurology 2002 Oct 8;59(7):998-1005.
    View PubMed
  101. O'Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschaner F, Kinkel RP, Bolibrush D, Cohen J, Freedman M, Webb U, Rabinowicz H, Metz LM, Patry D, Yeung M, Peters S, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, St Predictors of short-term disease activity following a first clinical demyelinating event: Analysis of the CHAMPS Placebo Group. Mult Scler. 2002 Oct;8(5):405-9.
    View PubMed
  102. O'Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschauer F, Kinkel RR, Bolibrush D, Cohen J, Freedman M, Webb U, Rabinowicz H, Metz L, Davis A, Patry D, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, Stuart D, Tor Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS Trial. Mult Scler. 2002 Aug; 8(4):330-8.
    View PubMed
  103. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002 Jul; 125(7):1450-61.
    View PubMed
  104. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M. Activity of a newly identified serine protease in CNS demyelination. Brain. 2002 Jun; 125(Pt 6):1283-96.
    View PubMed
  105. Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler. 2002 Apr; 8(2):93-7.
    View PubMed
  106. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M. Activity of a newly identified serine protease in immune-mediated demyelination. Brain. 2002; 125:1-14.
  107. Martinez-Arizala A, Barnes G, Benjamin S, Bowen J, Cutter N, Dietrich D, Dowling M, Griffin J, Irani D, Jorens P, Kaplin A, Katz J, Kerr D, Levy C, Lucchinetti CF, Lynn J, Mandler R, McDonald J, Morrison L, Pardo C, Pidcock F, Ransohoff R, Trovato M, Wege Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002:499-505.
  108. Targonski PV, Schiebel NE, Lucchinetti CN. Minocyoline-associated idiopathic intracranial hypertension in a patient presenting to the emergency department. Internet Journal of Emergency & Intensive Care Medicine. 2002; 6(1):8p.
  109. O'Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschauer F, Kinkel RP, Bolibrush D, Cohen J, Freedman M, Webb U, Rabinowicz H, Metz LM, Patry D, Yeung M, Peters S, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, St Interferon beta-1 a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001 Oct; 132(4):463-71.
  110. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol. 2001 Jun; 49(6):793-6.
    View PubMed
  111. Lucchinetti C, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol. 2001 Jun; 14(3):259-69.
    View PubMed
  112. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. 2001 Mar; 7(3):115-21.
    View PubMed
  113. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Invest. 2001 Mar; 81(3):263-81.
    View PubMed
  114. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 Sep 28; 343(13):938-52.
    View PubMed
  115. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW, the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000 Sep 28; 343(13):898-904.
    View PubMed
  116. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000 Jun; 47(6):707-17.
    View PubMed
  117. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain. 1999 Dec; 122 ( Pt 12):2279-95.
    View PubMed
  118. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec; 46(6):878-86.
    View PubMed
  119. Kuhlmann T, Lucchinetti C, Zettl UK, Bitsch A, Lassmann H, Bruck W. Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. Glia. 1999 Oct; 28(1):34-9.
    View PubMed
  120. Auger RG, Windebank AJ, Lucchinetti CF, Chalk CH. Role of the blink reflex in the evaluation of sensory neuronopathy. Neurology. 1999 Jul 22; 53(2):407-8.
    View PubMed
  121. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999 Mar; 103(6):807-15.
    View PubMed
  122. Drescher KM, Rivera-Quinones C, Lucchinetti CF, Rodriguez M. Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis. J Neuroimmunol. 1998 Aug 1; 88(1-2):111-9.
    View PubMed
  123. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998 Mar; 50(3):652-7.
    View PubMed
  124. Petty GW, Engel AG, Younge BR, Duffy J, Yanagihara T, Lucchinetti CF, Bartleson JD, Parisi JE, Kasperbauer JL, Rodriguez M. Retinocochleocerebral vasculopathy. Medicine (Baltimore) 1998 Jan; 77(1):12-40.
    View PubMed
  125. Weinshenker BG, Lucchinetti CF. Acute leukoencephalopathies: differential diagnosis and investigation. Neurologist. 1998; 4(3):148-66.
  126. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin Neurol. 1998; 18(3):337-49.
    View PubMed
  127. Lucchinetti CF, Kiers L, O'Duffy A, Gomez MR, Cross S, Leavitt JA, O'Brien P, Rodriguez M. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology. 1997 Nov; 49(5):1413-8.
    View PubMed
  128. Lucchinetti CF, Kimmel DW, Pavelko K, Rodriguez M. 5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus. Exp Neurol. 1997 Sep; 147(1):123-9.
    View PubMed
  129. Lucchinetti CF, Rodriguez M. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Mayo Clin Proc. 1997 Jul; 72(7):665-78.
    View PubMed
  130. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. Remyelination in multiple sclerosis. Mult Scler. 1997 Apr; 3(2):133-6.
    View PubMed
  131. Lucchinetti CF, Noseworthy JH, Rodriguez M. Promotion of endogenous remyelination in multiple sclerosis. Mult Scler. 1997 Apr; 3(2):71-75.
    View PubMed
  132. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 1996 Jul; 6(3):259-274.
    View PubMed
  133. Kerns JM, Lucchinetti C. Electrical field effects on crushed nerve regeneration. Exp Neurol. 1992 Jul; 117(1):71-80.
    View PubMed
  134. Kerns JM, Braverman B, Mathew A, Lucchinetti C, Ivankovich AD. A comparison of cryoprobe and crush lesions in the rat sciatic nerve. Pain. 1991 Oct; 47(1):31-9.
    View PubMed


Appointments | Contact Us | Give to Mayo Clinic | Search

LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE

Use of this site signifies your agreement to the terms of use.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.